Maya Gutierrez

5.4k total citations · 2 hit papers
31 papers, 3.0k citations indexed

About

Maya Gutierrez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Maya Gutierrez has authored 31 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Maya Gutierrez's work include HER2/EGFR in Cancer Research (11 papers), Brain Metastases and Treatment (10 papers) and Lung Cancer Research Studies (5 papers). Maya Gutierrez is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Brain Metastases and Treatment (10 papers) and Lung Cancer Research Studies (5 papers). Maya Gutierrez collaborates with scholars based in France, United States and United Kingdom. Maya Gutierrez's co-authors include Syed K. Mohsin, Susan G. Hilsenbeck, Gary C. Chamness, Jenny C. Chang, Richard Elledge, D. Craig Allred, C. Kent Osborne, Rachel Schiff, P. O’Connell and Anna Tsimelzon and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Maya Gutierrez

29 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

2003 668 citations Jenny C. Chang, Eric C. Wooten et al. The Lancet profile →
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

2012 522 citations Thomas Bachelot, Gilles Romieu et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maya Gutierrez France	19	1.9k	1.0k	925	911	371	31	3.0k
Judy Dering United States	23	2.2k 1.1×	1.5k 1.5×	1.3k 1.4×	902 1.0×	238 0.6×	41	3.6k
Dimitrios Zardavas Belgium	21	2.1k 1.1×	945 0.9×	854 0.9×	1.3k 1.4×	589 1.6×	69	3.3k
Kevin Kalinsky United States	30	2.1k 1.1×	853 0.8×	994 1.1×	728 0.8×	559 1.5×	150	3.1k
Florence Lerebours France	29	1.4k 0.7×	915 0.9×	692 0.7×	1.2k 1.3×	322 0.9×	97	2.6k
Zefei Jiang China	30	2.5k 1.3×	1.1k 1.1×	1.2k 1.3×	915 1.0×	744 2.0×	198	3.8k
Stacy L. Moulder United States	32	2.5k 1.3×	1.4k 1.4×	922 1.0×	1.3k 1.4×	589 1.6×	141	3.9k
Alexey Manikhas Russia	23	3.1k 1.6×	880 0.9×	1.4k 1.5×	1.4k 1.5×	763 2.1×	89	3.9k
Mónica Arnedos France	25	1.6k 0.8×	1.4k 1.4×	1.0k 1.1×	1.2k 1.3×	175 0.5×	90	3.1k
Giancarlo Bisagni Italy	25	1.9k 1.0×	570 0.6×	832 0.9×	747 0.8×	918 2.5×	127	2.9k
Patricia Galván Spain	20	1.4k 0.7×	947 0.9×	671 0.7×	997 1.1×	263 0.7×	69	2.4k

Countries citing papers authored by Maya Gutierrez

Since Specialization

Citations

This map shows the geographic impact of Maya Gutierrez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maya Gutierrez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maya Gutierrez more than expected).

Fields of papers citing papers by Maya Gutierrez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maya Gutierrez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maya Gutierrez. The network helps show where Maya Gutierrez may publish in the future.

Co-authorship network of co-authors of Maya Gutierrez

This figure shows the co-authorship network connecting the top 25 collaborators of Maya Gutierrez. A scholar is included among the top collaborators of Maya Gutierrez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maya Gutierrez. Maya Gutierrez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gutierrez, Maya, Émilie Le Rhun, Olivier Trédan, et al.. (2022). Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro-Oncology. 25(2). 365–374. 30 indexed citations

Azzopardi, Nicolas, Claire Bonneau, Céline Desvignes, et al.. (2021). Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. Clinical Pharmacology & Therapeutics. 110(1). 210–219. 7 indexed citations

Gutierrez, Maya, et al.. (2018). Santé connectée, relation de soins et éthique. La Revue de l Infirmière. 67(240). 29–29.

Bonneau, Claire, Gilles Paintaud, Olivier Trédan, et al.. (2018). Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. European Journal of Cancer. 95. 75–84. 66 indexed citations

Bachelot, Thomas, José Á. García-Sáenz, Sunil Verma, et al.. (2014). Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer. 14(1). 166–166. 19 indexed citations

Baffert, Sandrine, Paul Cottu, Youlia Kirova, et al.. (2013). Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study. BMC Health Services Research. 13(1). 456–456. 6 indexed citations

Bachelot, Thomas, Gilles Romieu, Mario Campone, et al.. (2012). Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. The Lancet Oncology. 14(1). 64–71. 522 indexed citations breakdown →

Elghissassi, Ibrahim, et al.. (2012). Long term response to erlotinib in a patient with recurrent vulvar carcinoma: Case report and review of literature. PubMed. 2(4). 119–120. 6 indexed citations

Chen, Albert C., Ilenia Migliaccio, Mothaffar F. Rimawi, et al.. (2012). Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Research and Treatment. 134(2). 583–593. 28 indexed citations

10.

Scodan, Romuald Le, Christophe Massard, Maya Gutierrez, et al.. (2011). Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer. 11(1). 395–395. 48 indexed citations

11.

Elghissassi, Ibrahim, et al.. (2011). Renal Cell Carcinoma with Gastric Metastases. Journal of Gastrointestinal Cancer. 43(S1). 181–183. 3 indexed citations

12.

Gutierrez, Maya, et al.. (2011). Méningites carcinomateuses des cancers du sein surexprimant HER2 : pour un traitement spécifique ?. Bulletin du Cancer. 98(4). 417–424. 6 indexed citations

13.

Dave, Bhuvanesh, Ilenia Migliaccio, Maya Gutierrez, et al.. (2010). Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers. Journal of Clinical Oncology. 29(2). 166–173. 190 indexed citations

14.

Chang, Jenny C., Andreas Makris, Maya Gutierrez, et al.. (2007). Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Research and Treatment. 108(2). 233–240. 107 indexed citations

15.

Mohsin, Syed K., Maya Gutierrez, Heidi L. Weiss, et al.. (2005). Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Research and Treatment. 94(3). 279–284. 20 indexed citations

16.

Mohsin, Syed K., Heidi L. Weiss, Maya Gutierrez, et al.. (2005). Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers. Journal of Clinical Oncology. 23(11). 2460–2468. 183 indexed citations

17.

Vallat, Laurent, Yves Benhamou, Maya Gutierrez, et al.. (2004). Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis & Rheumatism. 50(11). 3668–3678. 86 indexed citations

18.

Mohsin, Syed K., Richard Elledge, Susan G. Hilsenbeck, et al.. (2003). Neoadjuvant Trastuzumab and Docetaxel in Patients With Breast Cancer: Preliminary Results. Clinical Breast Cancer. 4(5). 348–353. 67 indexed citations

19.

Chang, Jenny C., Eric C. Wooten, Anna Tsimelzon, et al.. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. The Lancet. 362(9381). 362–369. 668 indexed citations breakdown →

20.

Gutierrez, Maya, et al.. (1992). Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons. Cancer Immunology Immunotherapy. 35(5). 315–324. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact